Enterprise Value

-1.346M

Cash

25.45M

Avg Qtr Burn

-10.9M

Short % of Float

8.73%

Insider Ownership

1.07%

Institutional Own.

0.00%

Qtr Updated

12/31/22


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1/2

Data readout

CB-839 (Glutaminase Inhibitor Telaglenastat) Details
Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma

Phase 1/2

Update

CB-839 (Glutaminase Inhibitor Telaglenastat) Details
Non-small cell lung carcinoma, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

CB-659 (mivavotinib) Details
Non-Hodgkin lymphoma, Diffuse large B cell lymphoma

Failed

Discontinued

Failed

Discontinued